(January 23, 2012 – International Poultry Exposition, Atlanta, GA) – As one of the top three fastest growing veterinary pharmaceutical companies – and the 9th largest veterinary company in the world – Ceva is set to continue making its North American presence known. The leader in vector technology continues its commitment to the poultry industry by bringing innovation to veterinarians with the launch of Vectormune® HVT-LT. This vector vaccine protects against both Infectious Laryngotracheitis and Marek’s Disease.
Infectious Laryngotracheitis is a severe respiratory disease affecting broilers, layers and broiler breeders. Broilers specifically have been affected in the U.S. and Latin America since 2006.
Vectormune HVT-LT is the newest addition to a vaccine range that includes Vectormune FP LT, a vector vaccine solution for Pox and ILT widely used in the U.S. and Latin American for its demonstrated capacity to overcome the limitations of live CEO ILT vaccines with a protective, safe, and non-spreading alternative. This launch completes Ceva’s HVT-based vector vaccine range by offering veterinarians a single-supplier solution for Newcastle Disease, Infectious Laryngotracheitis, or Infectious Bursal Disease with Vectormune HVT-NDV, Vectormune HVT-LT or Vectormune® HVT-IBD.
Vectormune HVT-LT can be administered in the hatchery, in ovo, or at day of age. It provides lifelong protection and is extremely safe.
Vectormune HVT-LT is produced at Ceva’s new state-of-the-art facility at its Biomune Campus in Lenexa, Kansas, and completes Ceva’s domestic product line for ILT and Marek’s Disease protection.
The company also continues momentum from 2011 and heads into 2012 with recent Canadian acquisitions and continued investment in research and development.
In October, Ceva increased its global footprint by acquiring Vetech Laboratories, Inc. and CentaurVA Animal Health, both located in Guelph, Ontario. Vetech produces live coccidiosis vaccines under the trade name Immucox®. The Centaur acquisition further expands Ceva’s companion animal operations in North America; its range of products includes nutraceuticals, joint therapies and infection-control products.
“We are looking forward to our continued growth and development of new solutions. At the same time, our values guide what we do every day. While we grow, we remain committed to maintaining our entrepreneurial spirit, our commitment to innovation, and our solidarity as a team. It’s an exciting time at Ceva,” said Craig Wallace, Chief Executive Officer and North America Zone Director of Ceva Animal Health, LLC.
About Ceva Animal Health: Ceva’s key domestic poultry products include Vectormune® HVT-LT, CEVAC® Transmune IBD, Vectormune FP and Vectormune HVT. Ceva’s key companion animal products include the Vectra® line of parasiticides, Adaptil™ (formerly D.A.P.) and Feliway® pheromone behavior aids and Senilife® neuroprotection for aging pets. Ceva Biomune Campus and the North America Zone headquarters are both located in Lenexa, Kansas. Visit www.ceva.us.
About Ceva Santé Animale: Ceva’s parent company is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, swine and poultry. Its headquarters is in Libourne, France. Visit www.ceva.com.
For more information, please contact Carolyn Gilliland at carolyn.gilliland[at]ceva.com or 913.945.4448.